Latest news with #AcuityMD
Business Wire
5 days ago
- Business
- Business Wire
AcuityMD Makes the Forbes' 2025 'Next Billion-Dollar Startups' List
BOSTON--(BUSINESS WIRE)-- AcuityMD, the MedTech Intelligence Platform, has been named to Forbes' 2025 'Next Billion-Dollar Startups' list – an elite group of 25 venture-backed U.S. companies identified as most likely to reach a $1 billion valuation. The list has a strong track record: more than 100 startups named in the past 10 years have since become unicorns. AcuityMD stands out because the company is applying AI to deliver real ROI in the complex, underserved MedTech market. It's exactly the kind of business we believe will define the future of AI-powered vertical software. Share This recognition highlights AcuityMD's rapid growth and innovation since its inception in 2019. Over the past year, the company signed its 300th customer, launched two innovative products, and doubled its staff, including the addition of Brian Collins as Chief Product Officer. Collins brings decades of product leadership experience from Salesforce, Demandware, Oracle, and other category-defining companies. Following a $45 million Series B funding round in 2024, AcuityMD's total funding now exceeds $83 million. As the global medical devices market is expected to expand from about $542 billion in 2024 to $886 billion by 2032, AcuityMD is well-positioned to capitalize on this growth trajectory. 'Being named on the Forbes list is a testament to our team's dedication to customers and commitment to our mission: to accelerate the adoption of cutting-edge medical technologies,' said Mike Monovoukas, CEO and co-founder of AcuityMD. 'While we are grateful to be recognized, we remain grounded in the work ahead to help our customers bring breakthrough medical innovation to more patients.' AcuityMD combines real-world healthcare data, AI-powered insights, and intuitive workflows to give MedTech companies the information they need to grow market share and get their innovative technology to more patients faster. Its intelligence platform is trusted by leading MedTech companies, including Becton Dickinson, Teleflex, and Olympus. AcuityMD was also recently named to Newsweek's 'America's Greatest Startup Workplaces 2025.' The Forbes' 'Next Billion-Dollar Startups' list, now in its 11th year, is a solid indicator of startup success. Of the list's 250 alumni, 140 or 56%, have become unicorns, including DoorDash, Figma, Anduril, Benchling, and Rippling. 'AcuityMD stands out because the company is applying AI to deliver real ROI in the complex, underserved MedTech market," said Logan Bartlett, Managing Director at Redpoint, a venture capital firm focused on investments in seed, early and growth-stage companies. "It's exactly the kind of business we believe will define the future of AI-powered vertical software.' Forbes Methodology The selection process for Forbes' Next Billion-Dollar Startups list is grounded in a data-driven methodology that combines company-submitted information, input from venture capital firms, select third-party data, and historical trends. To qualify, companies must be private, venture-backed, based in the United States, and have a valuation under $1 billion at the time of consideration. The evaluation model prioritizes key quantitative metrics such as valuation and revenue, which carry the greatest weight, alongside other indicators including user or customer count and employee headcount. Each applicant is assessed within this multi-factor framework to identify startups demonstrating strong growth, scalability, and the potential to surpass the billion-dollar threshold in the near future. More on the methodology can be found here. About AcuityMD AcuityMD is the MedTech Intelligence Platform trusted by more than 300 MedTech companies – including six of the top 10. Commercial leaders use AcuityMD to identify target markets, surface top opportunities, and grow their business. By combining real-world healthcare data with AI-powered insights, AcuityMD enables companies from pre-commercial to enterprise to understand where and how to sell faster to accelerate the adoption of medical technology.
Forbes
6 days ago
- Business
- Forbes
Forbes Next Billion-Dollar Startups 2025
T his is the 11th year we have partnered with TrueBridge Capital Partners to scour the land for budding unicorns. To qualify, startups must be venture-backed, based in the U.S. and (currently) worth less than $1 billion. Unsurprisingly, artificial intelligence dominates this year—20 of the 25 companies are AI-focused, with applications in military, accounting and health tech. Pay attention to this list: Our track record is superb. Of the 250 alumni, 140, or 56%, became unicorns, including DoorDash, Figma and Anduril. Forty-two were acquired; only two went public for less than $1 billion. Just five—2% of our selections—have imploded or shut down. If you want to build medical devices, you need patients. Boston-based AcuityMD helps manufacturers find the right physicians based on the patients they treat by using de-identified data (think surgical histories, medical referrals) for 325 million people to craft marketing plans. Customers include Synchron, which used it to find patients for a brain-computer interface preclinical trial, and Intellijoint, which did so to market a new surgical tool for hip and knee replacements. There are lots of influencers on the internet, and finding the right one for an ad campaign can be frustrating and time-consuming. Enter New York City–based Agentio, which offers a marketplace of creators so brands can easily find which influencers will work best for them. It's great for the creators too: They simply upload details about their upcoming YouTube videos to Agentio to sell ad spots to businesses such as Away, DoorDash, Mint Mobile and Uber. The U.S. military and companies like Amazon and SpaceX are racing to launch thousands of small satellites into low-Earth orbit. Los Angeles–based Apex wants to speed up the process—and cut costs—by offering a standardized satellite that buyers can trick out with their own sensors and instruments. It's had early success with the Pentagon, winning a $46 million Space Force contract in February. (For more, see 'Apex Wants To Bring Henry Ford-Style Mass Production To Satellites.') Jeffery Liu (left) and Jon Wang Assort Health Hospitals and doctors' offices are continuously overwhelmed by phone calls, leading to annoyingly long hold times for patients. Assort Health, headquartered in San Francisco, sells a text-to-voice artificial intelligence chatbot to search physicians' calendars to match their openings with the type of appointment required. The software has cut wait times for millions of inbound calls to medical groups including, among others, Chesapeake Healthcare and Peninsula Orthopaedic Associates. Basis Founders: Matthew Harp (CEO), Mitchell Troyanovsky Equity raised: $37 million Estimated 2024 revenue: $350,000 Lead investors: BTV, Khosla Ventures This NYC tech outfit makes AI accounting software that can do clerical work in minutes, streamlining data entry tasks like transferring information from receipts. After adopting Basis' software in 2024, accounting firm Wiss claimed a nearly 30% reduction in time spent on such jobs. Another big draw is the technology's security features, which don't store sensitive login details. Braintrust Founder: Ankur Goyal (CEO) Equity raised: $45 million Estimated 2024 revenue: $2 million Lead investors: Andreessen Horowitz, Basecase, Gil Capital, Greylock AI promises business efficiencies, but how do you measure them? San Francisco–based Braintrust offers an all-in-one command center for testing and monitoring AI-powered apps, like keeping an eye on how frequently a chatbot gives incorrect answers. Customers such as Airtable, Instacart, Notion and Stripe use it to assess accuracy and figure out what went wrong when something breaks. CEO and founder Ankur Goyal, 35, previously founded AI search engine Impira, which Figma acquired in 2023. Browserbase Founder: Paul Klein IV (CEO) Equity raised: $68 million Estimated 2024 revenue: $1 million Lead investors: Basecase, CRV, Kleiner Perkins, Notable Capital Goodbye, browsers: Browserbase wants to change how we interact with the internet entirely. Instead of clicking, typing and scanning information from websites, AI can do it for you, a concept known as a 'headless browser.' Want to book a flight from Seattle to JFK? Instead of searching yourself, type a simple request into Browserbase and its AI will come back with the best options. Surbhi Sarna Cody Pickens for Forbes Collate Founders: Jigish Patel, Surbhi Sarna (CEO), Nate Smith Equity raised: $30 million Estimated 2024 revenue: $0 Lead investors: Redpoint When Surbhi Sarna tried to raise funds for her ovarian cancer startup nVision Medical in 2012, she struggled to scrape together $500,000. After selling it for $275 million in 2018 and spending the next five years as a partner at accelerator Y Combinator, Sarna had no problem raising $30 million in seed funding for San Francisco–based Collate. It aims to use AI to automate the paperwork required for life sciences companies, such as that for clinical trials and FDA approval. 'This stuff they would have spent months doing we can do over the course of days,' says Sarna, 39. Collate's revenue is expected to reach $1 million this year. David AI Founders: Tomer Cohen (CEO), Ben Wiley Equity raised: $30 million Estimated 2024 revenue: $1 million Lead investors: Alt Capital, Amplify Partners, First Round Capital Tomer Cohen, 27, and Ben Wiley, 26, believe that normal speech will be the main way we interact with artificial intelligence in the future. Their startup, David AI, supplies some 100,000 hours of high-quality voice audio in 15 languages to major tech firms, helping them build smarter AI models capable of understanding speech. They have a straightforward approach to getting all that data: David AI simply pays people to record it. Dean Leitersdorf Cody Pickens for Forbes Decart Founders: Dean Leitersdorf (CEO), Moshe Shalev Equity raised: $53 million Estimated 2024 revenue: $20 million Lead investors: Benchmark, Sequoia, Zeev Ventures Dean Leitersdorf has an ambitious goal: to build the next big all- purpose AI lab to rival OpenAI, Anthropic and Google. His entrant in the race is called Decart, a nod to René Descartes, the 17th-century French philosopher famous for the aphorism 'I think, therefore I am.' 'It's the most AI thing you could say,' says Leitersdorf, a 26-year-old computer science Ph.D. He thinks recruiting mainly out of his native Israel will give Decart a chance against the giants, and its first product helps businesses squeeze more power out of AI chips. Last year, Decart went viral when its model Oasis generated a clone of Microsoft's Minecraft game using nothing but AI. (Boy, we're good: Shortly after this list went to press, Decart became a full Billion-Dollar Startup after raising $100 million at a $3.1 billion valuation.) Josh Araujo Shawn Hubbard for Forbes Forterra Founders: Alberto Lacaze, Karl Murphy CEO: Josh Araujo Equity raised: $303 million Estimated 2024 revenue: $30 million Lead investors: Hedosophia, Moore Strategic Ventures, XYZ Venture Capital Engineers Alberto Lacaze, 55, and Karl Murphy, 65, spent about 20 years developing technology to retrofit more than 50 types of vehicles to drive themselves, including transit buses and military convoy trucks. Now the startup is cashing in, winning a $93 million contract from the U.S. Army to produce mine-clearing robots. It's also part of a team building self-driving missile launchers for the Marines. Getting rid of human drivers both keeps soldiers out of harm's way and saves lots of money on fuel, says CEO Josh Araujo, 45, who took the helm from Lacaze in 2022, since you can ditch heavy armor and use a smaller engine. 'You can completely reshape how you design those vehicles.' Gamma Founders: James Fox, Grant Lee (CEO), Jon Noronha Equity raised: $23 million Estimated 2024 revenue: $16 million Lead investors: Accel, Afore Capital, South Park Capital Former investment banker Grant Lee, 42, was inspired to start Gamma after spending years making traditional slide decks, often under time pressure and with little design support. Now his AI-powered software can spin up a slick presentation, website or social media post from raw text, documents or existing decks. Gamma says more than 50 million people globally have tried the product so far, and it has found early traction at companies including Amazon and Zoom. Graphite Founders: Greg Foster, Merrill Lutsky (CEO), Tomas Reimers Equity raised: $81 million Estimated 2024 revenue: $2 million Lead investors: Accel, Andreessen Horowitz, Homebrew New York City–based Graphite's flagship product, Diamond, is an AI assistant to speed up code reviews, in which programmers make sure their work is up to snuff, by flagging potential bugs and suggesting improvements. It's designed to understand context and reason about code like a human teammate, leading to adoption at fast-growing companies including Anysphere, Figma, Ramp and Shopify. Krea Founders: Victor Perez (CEO), Diego Rodriguez Equity raised: $83 million Estimated 2024 revenue: $5 million Lead investors: Abstract Ventures, Andreessen Horowitz, Bain Capital Ventures, Gradient Ventures, Pebblebed As AI revolutionizes creative work, many visual artists find themselves overwhelmed by the array of competing products. Krea, a design tool built by a team of musicians, poets, designers and videographers, offers visual artists one place to access a range of AI models that can generate new images from text prompts, refine existing ones or enhance video. The startup has attracted more than 20 million users globally, including from teams at Lego, Pixar and Microsoft. Lead Founders: Erica Khalili, Homam Maalouf, Jacqueline Reses (CEO), Ronak Vyas Equity raised: $110 million Estimated 2024 revenue: $170 million Lead investors: Andreessen Horowitz, Coatue, Khosla Ventures, Ribbit Partners, Zeev Ventures In 2022, former Square human resources chief Jacqueline Reses, now 55, and a team of investors acquired a nearly century-old community bank with the goal of transforming it into a fintech startup. That business, Kansas City, Missouri–based Lead Bank, is now one of the few FDIC-insured financial institutions that issue loans and process payments for fintechs and crypto startups. It recently launched a stablecoin debit card with Visa and payments platform Bridge. Livekit Founders: Russ d'Sa (CEO), David Zhao Equity raised: $82 million Estimated 2024 revenue: $5 million Lead investors: Altimeter Capital, Redpoint When you use voice mode on ChatGPT, your phone connects to a LiveKit server. The San Francisco–based startup provides the technical back end to enable real-time audio and video for a bunch of applications, including roughly 25% of 911 emergency calls in the U.S. In all, it's used by almost 125,000 developers at places like Meta and Microsoft and supports 3 billion calls every year. The company raised $45 million at a $345 million valuation in April. Celine Halioua Ethan Pines for Forbes Loyal Founder: Celine Halioua (CEO) Equity raised: $135 million Estimated 2024 revenue: $0 Lead investors: Bain Capital Ventures, Collaborative Fund, First Round Capital, Khosla Ventures, Longevity Fund, Valor Equity Partners Dogs don't live long enough. Celine Halioua—an Oxford Ph.D. dropout and former chief of staff at the first VC firm focused on longevity-related biotechs—started San Francisco-based Loyal to develop drugs that could delay their aging by targeting metabolic and hormonal imbalances before they become disease. The company's first beef-flavored longevity pill could hit the market by 2026, potentially extending dogs' lives—and perhaps someday ours as well. (For more, see 'Longer Leash On Life: Inside The Dog Longevity Startup.') Amar Hanspal Cody Pickens for Forbes Motif Founders: Amar Hanspal (CEO), Brian Mathews Equity raised: $46 million Estimated 2024 revenue: $0 Lead investors: CapitalG, Redpoint Architects at some 20 firms use Amar Hanspal's two-year-old software to design buildings and complex structures while collaborating with one another in real time. It's like Figma, but for architects. The tool, trained on thousands of floor plans and public data, uses AI to generate 3D layouts after designers specify details like the number of conference rooms, ceiling heights and window placements. Before starting Motif, Hanspal, 61, did a 15-year stint at Autodesk, the construction industry's $5.5 billion (2024 revenue) software incumbent. 'People are designing intelligent buildings. We want to build an intelligence system that assists them,' he says. Cameron McCord (CEO) Nominal Nominal Founders: Jason Hoch, Cameron McCord (CEO), Bryce Strauss Equity raised: $102 million Estimated 2024 revenue: $5 million Lead investors: General Catalyst, Lux Capital, Sequoia Capital Those who make planes, robots and drones want to move fast. But Cameron McCord, 35, an ex-Navy nuclear engineer who spent five years working at defense startups, believed they didn't have the right tech to manage product testing. Nominal, which he cofounded in 2022, sells software that collects and analyzes the results of trials of aircraft and other hardware. Customers include the U.S. Air Force, Palmer Luckey's drone outfit Anduril and seaplane developer Regent. Reducto Founders: Adit Abraham (CEO), Raunak Chowdhuri Equity raised: $33 million Estimated 2024 revenue: $1 million Lead investors: Benchmark, First Round Capital MIT grads Adit Abraham, 26, and Raunak Chowdhuri, 23, named their startup Reducto after the Harry Potter spell that shatters objects. Their mission is a little tamer: Reducto's AI software turns messy documents into clean, usable data. Similar to how a human would review paperwork, Reducto's tech scans documents multiple times to catch and fix mistakes. So far, it has processed over 250 million pages for companies including Scale AI, Vanta and Airtable. Misha Laskin Reflection AI Reflection AI Founders: Ioannis Antonoglou, Misha Laskin (CEO) Equity raised: $130 million Estimated 2024 revenue: $0 Lead investors: CRV, Lightspeed Venture Partners, Sequoia Capital In 2016, Google DeepMind researcher Ioannis Antonoglou, now 37, helped develop AlphaGo, the first AI to beat an elite human player at the board game Go. Eight years later, he teamed up with Laskin, 35, another former DeepMind researcher, to build Reflection AI, with the goal of building a 'superintelligence' that can write and maintain code. Most AI coding companies are still focused on tools that help developers, but Reflection wants to fully replace them. Gabriel Stengel alexander karnyukhin for forbes Rogo Founders: Tumas Rackaitis, Gabriel Stengel (CEO), John Willett Equity raised: $75 million Estimated 2024 revenue: $2 million Lead investors: AlleyCorp, Khosla Ventures, Thrive Capital New York City–based Rogo is building a chatbot to help junior bankers with time sucks like crunching numbers, preparing presentations and spreadsheets or doing basic research. Trained on financial datasets from places like Crunchbase and FactSet, the tool is used by some 10,000 busy juniors at firms including Tiger Global to trim hours from their 90-hour workweeks, says Gabriel Stengel, 27. With Rogo automating the gruntwork, bankers will be able to focus on more strategic tasks and building relationships with clients, he adds. Rox Founders: Ishan Mukherjee (CEO), Avanika Narayan, Diogo Ribeiro, Shriram Sridharan Equity raised: $50 million Estimated 2024 revenue: $0 Lead investors: General Catalyst, GV, Sequoia Ishan Mukherjee, 37, a former Apple engineer, started Rox in 2024. The startup, headquartered in San Francisco, builds AI 'agent swarms' that act like virtual assistants for sales teams—automating research, outreach and follow-ups so reps can focus on closing deals. Companies such as Ramp, MongoDB and Confluent are already using Rox to grow faster with fewer resources. Albert Pai (left) and Eric Simons Stackblitz Stackblitz Founders: Albert Pai, Eric Simons (CEO) Equity raised: $135 million Estimated 2024 revenue: $4 million Lead investors: Emergence, Greylock, GV, Insight In 2024, Eric Simons, 34, was on the verge of shuttering Stackblitz. The startup simply couldn't figure out how to make money from its browser-based coding tools. But when it embraced the 'vibe coding' AI software craze, its product, Bolt, took off. It allows people to build apps just by typing in a description. The company's customer base has surged to 5 million, with the company bringing in 85% of the year's revenue in just four months. John Hu Ethan Pines for Forbes Stan Founders: Vitalii Dodonov, John Hu (CEO) Equity raised: $5 million Estimated 2024 revenue: $25 million Lead investor: Forerunner Ventures Having millions of followers online doesn't immediately translate into a full-time salary. Stan tries to make it easier for those with online fame to cash in on their success with an online storefront linked to their social media profile. Stan, which claims to have achieved profitability after raising just $5 million from Forerunner Ventures back in 2022, provides an easy way for creators to sell their social media followers everything from personalized merch to coaching sessions. (For more, see 'This Startup Helps Creators Sell Classes, Coaching And More To Their Fans.') MORE FROM FORBES Forbes Next Billion-Dollar Startups 2024 By Amy Feldman Forbes Next Billion-Dollar Startups 2023 By Amy Feldman Forbes Next Billion-Dollar Startups 2022 By Amy Feldman
Business Wire
28-04-2025
- Business
- Business Wire
AcuityMD Expands Care Journeys Solution with Enhanced Physician Referral Networks to Increase Patient Access to MedTech Innovations
BOSTON--(BUSINESS WIRE)-- AcuityMD, the MedTech Intelligence Platform, today announced a new solution that will help MedTech companies and healthcare providers (HCPs) deliver new treatment options to more patients. Referral Pathways in AcuityMD Care Journeys provides comprehensive patient referral data so MedTech commercial teams can easily identify the physicians who can most benefit from their products and bring innovations to more patients. Referral Pathways in AcuityMD Care Journeys provides comprehensive patient referral data so MedTech commercial teams can easily identify the physicians who can most benefit from their products and bring innovations to more patients Share AcuityMD Care Journeys, launched in October 2024, was designed to help MedTech companies demonstrate the improved clinical and financial outcomes their technology delivers for patients with complex diagnoses and treatment journeys – helping them drive product adoption with hospitals and physicians. Now, AcuityMD is expanding its solution with sophisticated, data-driven visualizations to empower MedTech companies to connect upstream referrers to the HCPs offering their differentiated treatments. It gives a more complete view of the care journey, enabling teams to better target their innovations and improve outcomes for more patients. Supporting Overburdened Physicians According to a 2024 survey, 80% of physicians report being overworked. An aging patient population and more patients with comorbidities (i.e., obesity plus diabetes, asthma, sleep apnea, and kidney disease), combined with a serious physician shortage, makes it difficult for providers to stay current on the latest medical innovations. At the same time, MedTech companies are developing new technologies, thanks to advances in AI, robotics, and digital, at an unprecedented clip – in fact, the industry is expected to grow to $800 billion by 2030. The volume of innovation can overwhelm providers who are already feeling strained by high case volume, staffing challenges, and administrative responsibilities. They simply do not always have time to uncover the latest treatment options for their patients, nor research local doctors providing these new treatments and the outcomes patients are experiencing. MedTech companies have attempted to bridge this gap by hosting regional and local educational events with HCPs, but information blind spots remain. Comprehensive referral data is often lacking because it only captures a patient's most recent encounter. MedTech companies struggle to find all relevant HCPs who impact the patient journey, causing some patients to miss out on more effective treatments simply due to a lack of physician awareness. With AcuityMD's new Referral Pathways in Care Journeys, MedTech companies gain a comprehensive view of a provider's entire referral network to deliver better, consultative support. 'Referral Pathways takes MedTech commercialization to the next level, helping companies not only understand the clinical opportunity around an HCP, but also uncover new pathways for strategic referrals towards those HCPs,' said Megan Wilson, director of product management at AcuityMD. 'By identifying the doctors seeing the highest number of relevant patients and leveraging Referral Pathways, Care Journeys can help sales teams make smarter connections, and ultimately help ensure that patients receive the best possible care through the latest, most innovative treatments.' Uncovering Opportunities for Improved Care Referral Pathways goes beyond traditional referral data to uniquely map upstream HCPs diagnosing the specific conditions in the same location where HCPs offer a company's therapy. MedTech teams can leverage this to uncover referral connections that even the treating HCP didn't know existed. For example, Teleflex Incorporated, a global provider of medical technologies that offers solutions across therapy areas, including interventional urology, is leveraging Care Journeys to increase adoption of its minimally invasive UroLift(™) System. 'Over 14 million men in the U.S. are living with symptoms of BPH (enlarged prostate). We know their treatment journey is long, and only a small percentage (3%) elect to have a surgical intervention,' explained Anthony Parrillo, global vice president of marketing at Teleflex. 'Referral Pathways allows us to identify the healthcare providers diagnosing BPH most often in a given market, raise their awareness of the UroLift System procedure, and share with them the UroLift physician locator on our website. This new data from AcuityMD has been remarkable in helping us target more effectively and maximize our opportunity to deliver minimally invasive treatment.' Referral Pathways in AcuityMD Care Journeys is now generally available on the AcuityMD MedTech intelligence platform. Learn more this week at industry conferences: American Urological Association (AUA) Conference (April 26-29), where AcuityMD will be showcasing Care Journeys at booth #521. Device Talks Boston, where AcuityMD's Megan Wilson and Teleflex's Anthony Parrillo are presenting on Wednesday, April 30, in room 161. About AcuityMD AcuityMD is the MedTech Intelligence Platform for more than 300 MedTech companies – including six of the top 10. Commercial leaders use AcuityMD to identify target markets, surface top opportunities, and grow their business. With customers ranging from pre-commercial to enterprise, AcuityMD is committed to delivering the right insights, enabling companies to understand where and how to sell faster to accelerate the adoption of medical technology.
Associated Press
26-02-2025
- Business
- Associated Press
Profound Medical Standardizes on AcuityMD Intelligence Platform for MedTech as Foundation for Growing Organization
AcuityMD, the intelligence platform for the medical technology (MedTech) industry, has been selected by Profound Medical, a medical device company developing customizable, incision-free therapies that combine real-time magnetic resonance imaging, thermal ultrasound, and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue – specifically for prostate diseases. Profound Medical is standardizing its organization on AcuityMD's complete suite of commercial intelligence solutions to bring its breakthrough TULSA-PRO® technology to more healthcare providers nationwide. Nearly 60% of men diagnosed with low-risk prostate cancer are managed with active surveillance – a 'wait-and-see' approach – because traditional treatments often cause severe, permanent side effects such as incontinence and erectile dysfunction. Profound Medical provides patients with a better alternative for whole or partial gland ablation, whether for low-risk, intermediate-risk, or more severe disease states. Indicated for transurethral ultrasound ablation (TULSA) of prostate tissue, TULSA-PRO is the first incision-free, radiation-free treatment for prostate disease. The procedure, which is now reimbursed by Medicare with a Category 1 CPT code, can also be conveniently performed in various outpatient settings – hospitals, ambulatory surgery centers, and office-based laboratories (OBLs). AcuityMD provided Profound Medical a smart, efficient way to accelerate the delivery of TULSA-PRO to healthcare providers. Profound Medical had been using a general customer relationship management (CRM) system with spotty market data. As a fast-growing company, they needed a powerhouse system with integrated MedTech workflows that not only helped sales identify the providers that could benefit from TULSA-PRO but also incorporated reliable commercial intelligence to guide strategic decision-making. Profound Medical also wanted industry-specific functionality for territory, contract, and long-term customer engagement management. After reviewing AcuityMD's platform – including all modules Pipeline, Targeting, Markets, Territories, plus newer modules Contracts and Care Journeys, both launched in 2024 – and speaking to customer referrals, Profound Medical doubled-down on AcuityMD's entire suite. 'We are building something important and want to do it right alongside a technology provider that will partner with us as we grow,' said Tom Tamberrino, Chief Commercial Officer at Profound Medical. 'The people at AcuityMD are as driven to get TULSA-PRO into the market as we are, and their platform is proving instrumental to helping us identify which physicians are treating prostate disease and where, as well as uncovering the high-volume regions where we need to strategically hire more sales professionals.' Tamberrino added, 'We wanted a solution that was more than a one-note sales tool or generic CRM. AcuityMD provides value not just for our sales professionals but also our regional leaders, financial team, marketers, and even manufacturing groups. It's a comprehensive platform solution that delivers industry intelligence that all our teams can use for better decision-making.' AcuityMD's platform is built for the MedTech industry's unique commercialization process and combines streamlined workflows with robust data, enabling sales, marketing, and national accounts teams to build comprehensive strategies focused on their best opportunities. 'Profound Medical is solving a longstanding men's health problem by offering an innovative procedure for prostate disease that also preserves quality-of-life,' said Michael Monovoukas, CEO and co-founder of AcuityMD. 'We are proud to partner with Profound Medical to help identify their best opportunities so they can achieve their goals and bring revolutionary TULSA-PRO technology to as many patients as possible.' AcuityMD is the intelligence platform for MedTech. More than 300 MedTech companies – including six of the top 10 – use AcuityMD to identify target markets, surface top opportunities, and grow their business. With customers ranging from pre-commercial to enterprise, AcuityMD is committed to delivering the right insights so companies can understand where and how to sell faster to accelerate the adoption of medical technology. SOURCE: AcuityMD Copyright Business Wire 2025. PUB: 02/26/2025 07:05 AM/DISC: 02/26/2025 07:06 AM
